Landscapes / Companies
Cellectis S.A. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
2 in Phase 2
1 in Phase 1
Drugs
3
in active trials · 4 in all
Trials
3 active
4 since 2021
Drugs3
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 1/2 | Aug 2027Phase 1/2 trial completes | |||
| Next date | Aug 2027 · Phase 1/2 trial completes | ||||
| Also tested for | B-cell Non-Hodgkin Lymphoma (B-NHL) | ||||
| Open drug page | |||||
— |
Phase 1/2 | — | |||
| Also tested for | B-cell Acute Lymphoblastic Leukemia | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | Relapsed/Refractory Acute Myeloid Leukemia | ||||
| Open drug page | |||||
About
- No active trial
- UCARTCS1A
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021